Author

Raji Swamy

Observed names: R V Swamy, R. Swamy, R. V. Swamy, R.V. Swamy, Swamy, Raji

Institution: Regeneron (United States)

Observed institutions: Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, University of Pittsburgh, Genentech, Regeneron (United States), Defence Research and Development Establishment, Gilead Sciences (United States), Mayo Clinic in Florida, UCSF Helen Diller Family Comprehensive Cancer Center

OpenAlex ID: A5066660345

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

2011 · Adam M. Brufsky, Sara Hurvitz, et al. · Journal of Clinical Oncology · 421

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

2009 · A. Brufsky, I. Bondarenko, et al. · Cancer Research · 67

Chemistry and Toxicology of Sulphur Mustard- A Review

1999 · R. C. Malhotra, K. Ganesan, et al. · Defence Science Journal · 60

Structure-Activity Relationship Studies with Mosquito Repellent Amides

1991 · M.V.S. Suryanarayana, K.S. Pandey, et al. · Journal of Pharmaceutical Sciences · 47

Field evaluation of three repellents against mosquitoes, black flies & land leeches.

1984 · S Kumar, S Prakash, et al. · PubMed · 26

Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).

2010 · A. Brufsky, R. R. Rivera, et al. · Journal of Clinical Oncology · 25

Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI

2017 · Jose R. Arribas, Edwin DeJesus, et al. · HIV Clinical Trials · 17

Acute and subacute inhalation toxicity studies of a new broad spectrum insect repellent, N,N-diethylphenylacetamide

1991 · R. Vijayaraghavan, S.S. Rao, et al. · Toxicology · 13

Study on dermal toxicity and urinary metabolites of the new insect repellent N,N-diethylphenyl-acetamide in rabbits

1989 · S.S. Rao, M.K. Agarwal, et al. · Toxicology Letters · 13

Toxicity and metabolism of a new insect repellant N,N-diethylphenylacetamide in mice, rats and guinea pigs on cutaneous application

1989 · S.S. Rao, R.V. Swamy, et al. · Toxicology · 12

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials

2016 · Jun Yong Choi, Somnuek Sungkanuparph, et al. · Infection and Chemotherapy · 5

Mass Spectral Studies on Synthetic Analogues of Organophosphorus Toxin Isolated Fromptychodiscus Brevis

2000 · A. K. Gupta, S. K. Raza, et al. · Phosphorus, sulfur, and silicon and the related elements · 3

A First-in-human Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Regn7544, a Novel Natriuretic Peptide Receptor 1-blocking Monoclonal Antibody

2025 · Mohsin Ahmed, Katie Tuckwell, et al. · Journal of the American College of Cardiology

Works count: 14

Citation count: 709

H-index: 10

I10-index: 10